Laboratory and Clinical Features of Tumor Lysis Syndrome in Children with Non-Hodgkin Lymphoma

Anhar Hadad Alsulami[1], Mada Hamad Alshibani[2], Fatmah Mohamad Alotaibi[3], Fahad Saleh Alharbi[4], Rasha Lafi Alotaibi[5], Ghazwa Mesfer Alotaibi[6], Hasna Saad Alotaibi[7], Malak Mesfer Alotaibi[8], Reem Mahdi Ali Zugail[9], Alotaibi Abdullah Bander[10], Albatol Mohammed Hasan Hamad[11], Mamdouh Mohammed Alharthi[12], Munirah Fahad Alkhudhayr[13], Lamia Yousef Almanea[14], Khazma Hadi Alshahrani[14], Al-Anoud Fahd Al-Arwan[15]

[1] Biochemistry, PSMMC, Riyadh, Saudi Arabia.

[2] Microbiology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

[3] Microbiology, PSMMC, Riyadh, Saudi Arabia.

[4] Microbiology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia

[5] Medical laboratories (microbiology), Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

[6] Microbiology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

[7] Biochemistry, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

[8] Biochemistry, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

[9] Microbiology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

[10]Laboratory technician, PSMMC, Riyadh, Saudi Arabia.

[11]Laboratory, Prince Sultan military medical city, Riyadh, Saudi Arabia.

[12]Technician Laboratory – Microbiology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

[13]Medical Laboratory science - Laboratory Technician, Prince sultan military medical city, Riyadh, Saudi Arabia

[14]Medical laboratory, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

[15] Laboratory Technician, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Abstract

Tumor lysis syndrome (TLS) is a critical oncological emergency that can occur in children with non-Hodgkin lymphoma (NHL), particularly following the initiation of chemotherapy. This syndrome results from the rapid breakdown of malignant cells, leading to the release of intracellular components such as potassium, phosphate, and nucleic acids into the bloodstream. The subsequent metabolic derangements, including hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, can have severe clinical consequences, including acute kidney injury, cardiac arrhythmias, and neurological disturbances. The clinical presentation of TLS in pediatric patients can vary widely, ranging from asymptomatic laboratory abnormalities to life-threatening complications. Symptoms may include fatigue, nausea, palpitations, and seizures, often occurring within 24 to 48 hours after chemotherapy initiation. Laboratory findings are characterized by elevated serum levels of uric acid, potassium, and phosphate, alongside decreased calcium levels, necessitating prompt recognition and intervention. Risk factors for TLS in children with NHL include the type and stage of the lymphoma, the presence of a high tumor burden, and the specific chemotherapy regimen employed. Preventive strategies, such as aggressive hydration, the use of allopurinol or rasburicase, and close monitoring of metabolic parameters, are essential in mitigating the risk of TLS. Early recognition and intervention can significantly improve patient outcomes, highlighting the importance of vigilance in monitoring at-risk pediatric patients during chemotherapy.

Keywords: chemotherapy, Hyperuricemia, Asymptomatic, chemotherapy

Introduction

Tumor lysis syndrome (TLS) is a potentially life-threatening condition that can occur in patients with malignancies, particularly in those undergoing treatment for hematological cancers such as non-Hodgkin lymphoma (NHL). TLS is characterized by the rapid destruction of tumor cells, which leads to the release of intracellular components into the bloodstream. This phenomenon is particularly relevant in pediatric oncology, where children with NHL are at significant risk due to the aggressive nature of the disease and the intensive treatment regimens employed. The understanding of TLS is not merely an academic exercise; it is crucial for timely diagnosis and management, which can significantly impact patient outcomes and survival rates.

The incidence of TLS is notably higher in children with NHL compared to adults, primarily due to the unique biological behavior of pediatric lymphomas. Pediatric lymphomas, especially aggressive forms such as Burkitt lymphoma, exhibit rapid cell proliferation and high tumor burden, which can precipitate TLS. The swift onset of TLS often occurs within the first 24 to 48 hours after the initiation of chemotherapy, making it imperative for healthcare providers to be vigilant during this critical period. The rapid cell turnover, combined with the metabolic changes that occur during treatment, necessitates proactive management strategies to mitigate the risks associated with TLS.

In addition to the immediate clinical implications, TLS can have long-term consequences for pediatric patients. The metabolic derangements associated with TLS can lead to acute kidney injury, which may result in chronic renal impairment in some cases. This potential for long-term renal damage underscores the importance of early recognition and intervention. Furthermore, the psychological impact of experiencing a life-threatening condition during childhood can affect a patient's overall well-being and quality of life. Children may experience anxiety, depression, or post-traumatic stress symptoms as a result of their illness and the associated medical interventions.

Therefore, a comprehensive understanding of TLS is essential for healthcare providers involved in the care of children with NHL. This understanding should encompass not only the pathophysiology and clinical features of TLS but also the laboratory findings that aid in diagnosis, the risk factors that predispose patients to this syndrome, and the prevention strategies that can be employed to mitigate its occurrence. Additionally, effective management approaches must be established to address TLS promptly when it arises. By equipping healthcare providers with this knowledge, we can improve the care and outcomes for pediatric patients facing the challenges of non-Hodgkin lymphoma and its associated complications.

In summary, TLS represents a significant challenge in the management of pediatric NHL, necessitating a multifaceted approach that includes early identification, risk assessment, and timely intervention. The complexities of TLS highlight the need for ongoing education and research in this area, ensuring that healthcare providers are well-prepared to navigate the intricacies of this syndrome and provide optimal care for their young patients. As we delve deeper into the various aspects of TLS, it becomes increasingly clear that a proactive and informed approach is essential for improving the prognosis and quality of life for children affected by this serious condition.

Pathophysiology of Tumor Lysis Syndrome

The pathophysiology of TLS is rooted in the metabolic derangements that occur following the rapid lysis of malignant cells. When tumor cells are destroyed, they release large quantities of potassium, phosphate, and nucleic acids into the circulation. The breakdown of nucleic acids leads to the production of uric acid, which can accumulate and cause hyperuricemia. The release of potassium can result in hyperkalemia, while the release of phosphate can lead to hyperphosphatemia. These metabolic abnormalities can have profound effects on various organ systems, particularly the kidneys, heart, and nervous system.

The kidneys play a central role in the excretion of these metabolites. However, the rapid influx of potassium and phosphate can overwhelm the renal excretory capacity, leading to acute kidney injury. The kidneys are responsible for filtering blood and maintaining electrolyte balance, but the sheer volume of metabolites released during TLS can lead to tubular obstruction and interstitial nephritis. Additionally, the precipitation of calcium phosphate in the renal tubules can further exacerbate renal

dysfunction, leading to a vicious cycle of worsening metabolic derangements and renal impairment.

The clinical manifestations of TLS can vary widely, ranging from asymptomatic laboratory abnormalities to severe metabolic derangements that require immediate medical intervention. The severity of TLS is often classified based on the degree of metabolic abnormalities and the presence of clinical symptoms. In severe cases, TLS can lead to multi-organ failure, necessitating intensive care management and potentially life-saving interventions.

Clinical Features of Tumor Lysis Syndrome

The clinical presentation of TLS can be diverse, and it often depends on the severity of the metabolic derangements. In some cases, children may present with nonspecific symptoms such as fatigue, malaise, or nausea. These early symptoms can be easily overlooked, making it imperative for healthcare providers to maintain a high index of suspicion for TLS in at-risk patients. As the syndrome progresses, more severe symptoms may develop, including:

- **Hyperkalemia**: Elevated potassium levels can lead to cardiac arrhythmias, which may manifest as palpitations, syncope, or even sudden cardiac arrest. The risk of arrhythmias is particularly concerning in pediatric patients, as they may not exhibit the same warning signs as adults. Continuous cardiac monitoring is essential for early detection and intervention.
- **Hyperphosphatemia**: Elevated phosphate levels can result in soft tissue calcifications and acute kidney injury. The precipitation of calcium phosphate can lead to nephrocalcinosis, further impairing renal function and exacerbating the clinical picture.
- **Hypocalcemia**: This condition may lead to neuromuscular irritability, seizures, or tetany. The clinical manifestations of hypocalcemia can be particularly alarming, as they may mimic other neurological conditions, complicating the diagnostic process.

The timing of TLS is also an important consideration. It typically occurs within 24 to 48 hours after the initiation of chemotherapy, particularly in patients with high tumor burden or rapidly proliferating tumors. Therefore, close monitoring of at-risk patients during this critical period is essential for early detection and management of TLS. The clinical team should be prepared to act swiftly, as the rapid onset of TLS can lead to significant morbidity and mortality if not addressed promptly.

Laboratory Features of Tumor Lysis Syndrome

The laboratory features of TLS are characterized by a distinct pattern of metabolic abnormalities that can be identified through routine blood tests. Hyperuricemia is one of the hallmark findings, resulting from the breakdown of nucleic acids and the subsequent production of uric acid. Elevated serum uric acid levels can lead to the development of acute urate nephropathy, further complicating the clinical picture. The presence of uric acid crystals in the renal tubules can obstruct urine flow, leading to acute kidney injury and necessitating immediate intervention.

Hyperkalemia is another key laboratory finding in TLS. The rapid release of potassium from lysed tumor cells can lead to elevated serum potassium levels, which can have serious implications for cardiac function. Electrocardiographic changes associated with hyperkalemia may include peaked T waves, widening of the QRS complex, and, in severe cases, ventricular fibrillation. These changes can be life-threatening, particularly in pediatric patients who may have a lower threshold for cardiac complications.

Hyperphosphatemia is also commonly observed in TLS, resulting from the release of phosphate from lysed cells. Elevated phosphate levels can lead to the precipitation of calcium phosphate in tissues, contributing to acute kidney injury and other complications. Hypocalcemia, which may occur as a consequence of elevated phosphate levels, can lead to neuromuscular symptoms and further complicate the clinical picture. The interplay between these electrolytes is critical, as imbalances can exacerbate one another, leading to a cascade of metabolic disturbances.

In addition to these metabolic derangements, other laboratory findings may include elevated creatinine levels, indicating renal impairment, and alterations in liver function tests, which may reflect hepatic involvement in the context of malignancy. The assessment of these laboratory parameters is essential for the timely diagnosis of TLS and for guiding appropriate management strategies.

Risk Factors for Tumor Lysis Syndrome

Certain factors can increase the risk of developing TLS in children with NHL. These include the type and stage of the lymphoma, the presence of a high tumor burden, and the specific chemotherapy regimen employed. Children with aggressive forms of NHL, such as Burkitt lymphoma, are particularly susceptible to TLS due to the rapid proliferation of tumor cells. The high cell turnover rate in these aggressive lymphomas leads to a greater release of intracellular components into the bloodstream, increasing the likelihood of metabolic derangements.

Additionally, pre-existing renal dysfunction or dehydration can further increase the risk of TLS. Children with compromised renal function may have a reduced ability to excrete the excess potassium and phosphate released during tumor lysis, making them more vulnerable to the effects of TLS. Dehydration can exacerbate these issues by impairing renal perfusion and further limiting the kidneys' ability to manage electrolyte imbalances.

The use of certain chemotherapeutic agents, particularly those that are highly cytotoxic, can also contribute to the development of TLS. Agents such as cyclophosphamide, doxorubicin, and high-dose methotrexate are commonly associated with TLS in pediatric patients. The choice of chemotherapy regimen should take into account the potential for TLS, and healthcare providers should be vigilant in monitoring patients receiving these agents. Therefore, careful consideration of these risk factors is essential for the prevention and management of TLS in children with NHL.

Prevention of Tumor Lysis Syndrome

Preventive measures play a crucial role in managing the risk of TLS in children with NHL. The identification of at-risk patients is the first step in prevention. This involves assessing the patient's tumor burden, the aggressiveness of the lymphoma, and any pre-existing conditions that may predispose them to TLS. Hydration is a cornerstone of prevention, as it helps to dilute serum electrolytes and promote renal excretion of metabolic byproducts. Intravenous fluids are often administered prior to and during chemotherapy to maintain adequate hydration. The volume and rate of fluid administration should be tailored to the individual patient's needs, taking into account their baseline hydration status and renal function.

Additionally, the use of allopurinol, a xanthine oxidase inhibitor, can be beneficial in preventing hyperuricemia by reducing the production of uric acid from purine metabolism. Allopurinol is typically initiated before the start of chemotherapy and continued for several days afterward to provide ongoing protection against hyperuricemia. In some cases, rasburicase, an enzyme that catalyzes the conversion of uric acid to allantoin, may be used for patients at high risk of TLS, particularly those with high tumor burden or rapid cell turnover. This approach can significantly lower uric acid levels and mitigate the risk of acute kidney injury.

Monitoring is another critical component of TLS prevention. Regular assessment of serum electrolytes, uric acid levels, and renal function tests should be conducted, especially during the first few days of chemotherapy. This allows for the early detection of metabolic abnormalities and timely intervention to prevent the progression of TLS. The frequency of monitoring may need to be increased for patients identified as high risk, ensuring that any changes in laboratory values are addressed promptly.

Management of Tumor Lysis Syndrome

In the event that TLS does occur, prompt management is essential to mitigate its complications. The initial step involves the stabilization of the patient, which may include the administration of intravenous fluids to correct electrolyte imbalances and maintain renal perfusion. The choice of fluids is critical; isotonic saline is often preferred to ensure adequate hydration and promote diuresis. In cases of severe hyperkalemia, immediate measures such as the administration of calcium gluconate or calcium chloride may be necessary to protect the heart, followed by insulin and glucose to facilitate the cellular uptake of potassium. This combination helps to lower serum potassium levels quickly and reduce the risk of life-threatening cardiac arrhythmias.

For hyperuricemia, the use of rasburicase can rapidly lower uric acid levels, while allopurinol may be continued for ongoing management. Rasburicase is particularly effective in patients with high uric acid levels, as it converts uric acid into allantoin, a more soluble compound that can be easily excreted

by the kidneys. In cases of acute kidney injury, renal replacement therapy may be required, particularly if there is significant electrolyte imbalance or fluid overload. Continuous renal replacement therapy (CRRT) may be considered in critically ill patients, as it allows for more gradual correction of metabolic derangements and is better tolerated in unstable patients.

Monitoring for complications is also crucial during the management of TLS. Continuous cardiac monitoring is recommended for patients with hyperkalemia to detect arrhythmias early. Neurological assessments should be performed to identify any signs of seizures or altered mental status due to metabolic derangements. Additionally, regular monitoring of renal function, including serum creatinine and urine output, is essential to assess the effectiveness of interventions and to guide further management decisions.

In cases where TLS leads to multi-organ dysfunction, a multidisciplinary approach may be necessary. Involving nephrologists, intensivists, and other specialists can help optimize patient care and improve outcomes. The management of TLS is not only about addressing the immediate metabolic derangements but also about providing supportive care to ensure the overall well-being of the patient.

Conclusion

Tumor lysis syndrome is a serious complication that can arise in children with non-Hodgkin lymphoma, particularly during the initiation of chemotherapy. Understanding the laboratory and clinical features of TLS is vital for early recognition and intervention. The pathophysiology of TLS involves complex metabolic changes that can lead to significant morbidity and mortality if not managed appropriately. By implementing preventive strategies, closely monitoring at-risk patients, and providing timely management, healthcare providers can improve outcomes for children affected by this condition. Continued research into the mechanisms of TLS and the development of more effective preventive and therapeutic strategies will be essential in enhancing the care of pediatric patients with non-Hodgkin lymphoma. The integration of new technologies and treatment modalities may further refine our approach to managing this challenging syndrome, ultimately leading to better survival rates and quality of life for affected children.

References:

1. "Prevalence of Tumor Lysis Syndrome in Acute Leukemia and Lymphoreticular Malignancies: A Regional Study from PGIMS, Rohtak" Journal of medical science and clinical research (2021) doi:10.18535/jmscr/v9i3.16
2. Javed "Urate Nephropathy from Tumor Lysis Syndrome in an Undiagnosed Case of Prostate Cancer" Current oncology (2021) doi:10.3390/curroncol28010046
3. Cao et al. "Steroid-Induced Tumor Lysis Syndrome Accompanied by Diabetic Ketoacidosis and Acute Renal Failure in a Non-Hodgkin Lymphoma Patient" Cureus (2022) doi:10.7759/cureus.24491
4. Mainardi et al. "A Rare Case of Tumor Lysis Syndrome" The medicine forum (2015) doi:10.29046/tmf.015.1.015
5. Mirrakhimov et al. "Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature" Rare tumors (2014) doi:10.4081/rt.2014.5389
6. Fa'Ak et al. "A Case Report of Atezolizumab Induced Tumor Lysis Syndrome" American journal of case reports (2019) doi:10.12659/ajcr.915351
7. Vodopivec et al. "An Unusual Presentation of Tumor Lysis Syndrome in a Patient with Advanced Gastric Adenocarcinoma: Case Report and Literature Review" Case reports in medicine (2012) doi:10.1155/2012/468452
8. Wang "Clinical Features, Treatment, and Outcome of Tumor Lysis Syndrome in Germ Cell Tumors" Journal of urology & nephrology studies (2019) doi:10.32474/juns.2019.01.000116
9. Liaqat et al. "Spontaneous Tumor Lysis Syndrome in Myeloproliferative Disorder: A Rarely Reported Clinical Entity" American journal of medical case reports (2020) doi:10.12691/ajmcr-8-10-10
10. Smedts et al. "Acute Uterine Torsion Mimicking Tumor Lysis Syndrome" (2020) doi:10.31487/j.jscr.2020.02.03
11. Sommerhalder et al. "Spontaneous tumor lysis syndrome in colon cancer: a case report and

literature review" Clinical case reports (2017) doi:10.1002/ccr3.1269
12. Salsamendi et al. "Acute tumor lysis syndrome after proximal splenic artery embolization" Radiology case reports (2016) doi:10.1016/j.radcr.2016.02.001
13. Brener et al. "Bruton's tyrosine kinase inhibitors and the kidney: Focus on ibrutinib" Journal of oncology pharmacy practice (2020) doi:10.1177/1078155220904406
14. Shah et al. "Pembrolizumab-axitinib-induced tumor lysis syndrome in a patient with metastatic renal cancer" Clinical case reports (2020) doi:10.1002/ccr3.2737
15. Vanhise et al. "Tumor lysis syndrome in a patient with ovarian yolk sac tumor" Gynecologic oncology reports (2017) doi:10.1016/j.gore.2017.11.004
16. Cohen et al. "Tumor Lysis Syndrome: Introduction of a Cutaneous Variant and a New Classification System" Cureus (2021) doi:10.7759/cureus.13816
17. Frestad et al. "Acute onset and rapid progression of multiple organ failure in a young adult with undiagnosed disseminated colonic adenocarcinoma" Bmj case reports (2014) doi:10.1136/bcr-2014-205002
18. Dhanraj and Dubashi "Tumor lysis syndrome in multiple myeloma treated with bortezomib" Journal of pharmacology and pharmacotherapeutics (2014) doi:10.4103/0976-500x.130091
19. Atchison and Humes "A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma" Clinical nephrology - case studies (2017) doi:10.5414/cncs109165
20. D'Alessandro et al. "Severe Spontaneous Acute Tumor Lysis Syndrome and Hypoglycemia in Patient with Germ Cell Tumor" Tumori journal (2010) doi:10.1177/548.6530
21. Mcghee-Jez et al. "Spontaneous Tumor Lysis Syndrome as Presenting Sign of Metastatic Prostate Cancer" Cureus (2018) doi:10.7759/cureus.3706
22. Belay et al. "Tumor Lysis Syndrome in Patients with Hematological Malignancies" Journal of oncology (2017) doi:10.1155/2017/9684909
23. Mastoor et al. "Interrelationship of Electrolyte and Vitamins Profile in Patients Experiencing Tumor Lysis Syndrome" (2021) doi:10.53350/pjmhs211571597
24. Edayattil et al. "Fatal Spontaneous Tumor Lysis Syndrome: A Rare Presentation in Sarcomatoid Carcinoma" Journal of case reports (2023) doi:10.17659/01.2023.0005
25. (2020). Tumor lysis syndrome after chemotherapy for metastatic colic carcinoma: about two adult cases. archives of clinical gastroenterology, 017-019. https://doi.org/10.17352/2455-2283.000071
26. (2017). Tumor lysis syndrome following a single atezolizumab infusion for metastatic urothelial carcinoma involving both upper and lower tract. archives in cancer research, 05(01). https://doi.org/10.21767/2254-6081.1000127
27. (2016). Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency. expert review of hematology, 9(2), 197-208. https://doi.org/10.1586/17474086.2016.1127156
28. (2022). Tumor lysis syndrome. medicinski pregled, 75(Suppl. 1), 157-160. https://doi.org/10.2298/mpns22s1157p
29. (2012). Clinical course and prognostic factors of children with burkitt's lymphoma in a developing country: the experience of a single centre in brazil. revista brasileira de hematologia e hemoterapia, 34(5), 361-366. https://doi.org/10.5581/1516-8484.20120093
30. (2021). Fluid overload and acute kidney injury in children with tumor lysis syndrome. pediatric blood & cancer, 68(12). https://doi.org/10.1002/pbc.29255
31. (2016). Tumor lysis syndrome in multiple myeloma: an increasingly recognized risk—a report of seven cases. indian journal of hematology and blood transfusion, 33(1), 41-44. https://doi.org/10.1007/s12288-016-0731-6
32. (2016). Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: a case report. journal of oncology pharmacy practice, 23(3), 235-239. https://doi.org/10.1177/1078155216637218
33. (2019). You can't always blame the chemo: a rare case of spontaneous tumor lysis syndrome in a patient with invasive ductal cell carcinoma

of the breast. cureus. https://doi.org/10.7759/cureus.6186
34. (2017). Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature. journal of medical case reports, 11(1). https://doi.org/10.1186/s13256-017-1241-3
35. (2022). Comment on: fluid overload and acute kidney injury in children with tumor lysis syndrome. pediatric blood & cancer, 69(5). https://doi.org/10.1002/pbc.29609
36. (2015). A rare occurrence of metastatic gastric adenocarcinoma causing acute spontaneous tumor lysis syndrome and acute renal failure: a case report and review of the literature. international journal of cancer and oncology, 2(2), 1-4. https://doi.org/10.15436/2377-0902.15.016